



	Data disclosure form (Currency EUR)  2021 HCP/HCO Disclosure Date of publication: 30/06/2022												
			Country of Principal Practice	Principal Practice Address	Unique country identifier (OPTIONAL)		Contribution to costs of Events			Fee for service and consultancy		- 61 pusification: 30/00/2022	
	Full name	HCPs: City of Principal Practice HCOs: City where registered					Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event		Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	TOTAL (OPTIONAL)	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
ž	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
오	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A	0,00	0,00	0,00	0,00	Optional	
	Number of Recipients in aggregate disclosure					N/A	N/A	0	0	0	0	N/A	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					N/A	N/A	0%	0%	0%	0%	N/A	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
8.		'		'	OTHER, NOT INCI	UDED ABOVE - where information can	not be disclosed on an individual bas	is for legal reasons	'	•	•		
5	Aggregate amount attributable to transfers of value to such Recipients					0,00	0,00	0,00	0,00	0,00	0,00	Optional	
	Number of Recipients in aggregate disclosure						0	0	0	0	0	N/A	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						0%	0%	0%	0%	0%	N/A	

Q	AGGREGATE DISCLOSURE						
82	Transfers of Value re Research & Development as defined	134,775,90					